Overview

Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections

Status:
Completed
Trial end date:
2021-05-29
Target enrollment:
Participant gender:
Summary
It is a single-center, randomized, open-label, phase IV study for the explorative investigation of the pharmacological mode-of-action of Echinaforce® extract in the form of Echinaforce® Chewable tablets"- Further, it is aimed to evaluate the effectiveness of the study product for the prevention and treatment of respiratory tract infections in generally healthy adults following a real-life setting. The study covers 2x2 + 1 month of prevention in 120 randomized participants following a tight sampling set-up for sensitive detection of viral infections by RT-qPCR analysis of nasal swabs and seroconversion of SARS-CoV2 IgG/IgM in serum samples.
Phase:
Phase 4
Details
Lead Sponsor:
A. Vogel AG
Collaborators:
Biodome Clinical
Bodimed
CONVEX CRO
d.s.h. statistical services GmbH
MediStat Ltd.
PPES lab epigenetic signaling